Gout medication trial offers hope for artery disease

Peripheral artery disease affects one in five Australians over 75, causing narrowing of arteries that supply blood to the lower limbs, which can lead to leg pain, gangrene and amputation if untreated. A landmark clinical trial at Monash University is investigating whether colchicine, a long-used gout medication with anti-inflammatory properties, can delay disease progression and prevent severe complications. The affordable, readily accessible medication has already shown benefits in coronary artery patients, and researchers hope to demonstrate similar results for peripheral vascular disease.

See omnystudio.com/listener for privacy information.